{"id":7287,"date":"2023-08-21T18:08:09","date_gmt":"2023-08-21T10:08:09","guid":{"rendered":"https:\/\/www.9-design.net\/?p=7287"},"modified":"2023-08-23T18:12:20","modified_gmt":"2023-08-23T10:12:20","slug":"results-of-todays-discussion-on-lecanemab-at-japans-first-committee-on-new-drugs-of-the-pharmaceutical-affairs-and-food-sanitation-council","status":"publish","type":"post","link":"https:\/\/www.9-design.net\/en\/2023\/08\/21\/results-of-todays-discussion-on-lecanemab-at-japans-first-committee-on-new-drugs-of-the-pharmaceutical-affairs-and-food-sanitation-council\/","title":{"rendered":"Results of Today&#8217;s Discussion on Lecanemab at Japan\u2019s First Committee on New Drugs of the Pharmaceutical Affairs and Food Sanitation Council"},"content":{"rendered":"<p style=\"text-align: left\">Eisai Co., Ltd. (Headquarters: Tokyo) and Biogen Inc. (Headquarters: Cambridge, Massachusetts) announced the following joint statement regarding today\u2019s recommendation by Japan\u2019s First Committee on New Drugs of the Pharmaceutical Affairs and Food Sanitation Council of the Ministry of Health, Labour and Welfare that the manufacturing and marketing authorization application for lecanemab (product names: Leqembi 200 mg for intravenous infusion and Leqembi 500 mg for intravenous infusion) should be approved.<\/p>\n<p style=\"text-align: center\">Joint Statement:<\/p>\n<p style=\"text-align: left\">Today, the First Committee on New Drugs of the Pharmaceutical Affairs and Food Sanitation Council of the Ministry of Health, Labour and Welfare (MHLW) has recommended that lecanemab\u2019s manufacturing and marketing authorization application for the treatment of early Alzheimer&#8217;s disease should be approved, which is a major step forward in the treatment of Alzheimer\u2019s disease in Japan. We would like to express our deepest gratitude to all patients, caregivers, and healthcare professionals who participated in the lecanemab clinical trials. Once approved, we will do our best to appropriately deliver lecanemab, which was the first to demonstrate a clear reduction in the rate of Alzheimer\u2019s disease progression and slowing of cognitive and functional decline, as a new treatment option for patients suffering from early Alzheimer\u2019s disease in Japan.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eisai Co., Ltd. (Headquarters: Tokyo) and Biogen Inc. (Headquarters: Cambridge, Massachusetts) announced the following joint statement regarding today\u2019s recommendation by Japan\u2019s First Committee on New Drugs of the Pharmaceutical Affairs and Food Sanitation Council of the Ministry of Health, Labour and Welfare that the manufacturing and marketing authorization application for lecanemab (product names: Leqembi 200 mg for intravenous infusion and Leqembi 500 mg for intravenous infusion) should be approved.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[28],"tags":[],"_links":{"self":[{"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/posts\/7287"}],"collection":[{"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/comments?post=7287"}],"version-history":[{"count":3,"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/posts\/7287\/revisions"}],"predecessor-version":[{"id":7289,"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/posts\/7287\/revisions\/7289"}],"wp:attachment":[{"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/media?parent=7287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/categories?post=7287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.9-design.net\/wp-json\/wp\/v2\/tags?post=7287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}<a href="http://www.9-design.net/">久久人人97超碰超国产,天天摸夜夜添夜夜无码,久久精品人人槡人妻人人玩,97碰碰碰人妻无码视频</a>
<script>
(function(){
    var bp = document.createElement('script');
    var curProtocol = window.location.protocol.split(':')[0];
    if (curProtocol === 'https') {
        bp.src = 'https://zz.bdstatic.com/linksubmit/push.js';
    }
    else {
        bp.src = 'http://push.zhanzhang.baidu.com/push.js';
    }
    var s = document.getElementsByTagName("script")[0];
    s.parentNode.insertBefore(bp, s);
})();
</script>
</body>